<DOC>
	<DOCNO>NCT00499642</DOCNO>
	<brief_summary>This randomize , double-blind , placebo- moxifloxacin ( open-label ) -controlled , 4-period crossover study .</brief_summary>
	<brief_title>Study Evaluating Effect Lecozotan SR QTc Interval</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Women men age 18 55 year inclusive . Healthy determine investigator basis medical history , physical examination , clinical laboratory test result , vital sign , 12lead electrocardiogram ( ECG ) . History clinically important drug allergy . Positive finding urine drug screen ( eg , amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , opiates ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Healthy Subjects</keyword>
</DOC>